Daiichi Sankyo, Japan's No.3 drugmaker, said on Friday it believes it has made progress

RELATED ARTICLES Anti-trust lawsuit filed against Pfizer, Ranbaxy Daiichi Sankyo reports Q3 net loss of 19.5b yen US settlement puts Ranbaxy on the ropes Ranbaxy tumbles 7% on consent decree Ranbaxy faces possibility of a permanent injunction in US

towards lifting a U.S. ban on exports from Ranbaxy aboratories'(RANB.BO) two plants in India.

Ranbaxy, Daiichi Sankyo's Indian generic drug arm, recently submitted an internal report, which was compiled in cooperation with a third party, to U.S. regulators at the authorities' request, a Daiichi Sankyo spokesman said, citing the company's president Joji Nakayama.

Nakayama did not specify when he expected the ban to be lifted, the spokesman said.